ClinicalTrials.gg
RecruitingNCT07230652Updated Nov 19, 2025

A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020

A Phase 1 interventional study of LY03020 and Placebo in Schizophrenia and Alzheimer's Disease Psychosis, sponsored by Luye Pharma Group Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Luye Pharma Group Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 2 months later.
Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled, ascending multiple oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects and/or subjects with stable schizophrenia.

02

Conditions studied

  • Schizophrenia
  • Alzheimer's Disease Psychosis

Browse trials for

03

In context

Schizophrenia

3,563 studies on the registry are indexed under Schizophrenia; 491 are open to participants now.

This study's planned enrollment of 40 is below the median of 71 across 2,944 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

Luye Pharma Group Ltd. is the lead sponsor of 74 studies on the registry; 15 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy Subjects

  • Subjects sign voluntarily.
  • Male or female aged 18 to 45 years.
  • Body weight ≥ 50.0 kg for male and ≥ 45.0 kg for female, and (BMI) between 18.5 and 26.0 kg/m2 Subjects with Stable Schizophrenia
  • Subjects themselves and / or their guardians sign informed consent voluntarily.
  • Male or female aged 18 to 60 years.
  • Body weight ≥ 50.0 kg for male and ≥ 45.0 kg for female, and body mass index (BMI) between 18.5 and 32.0 kg/m2.
  • Subject must meet the criteria for a primary diagnosis of schizophrenia. Subject must have a PANSS total score ≤ 80 and CGI-S score ≤ 4 at screening. The condition is stable from 1 month before signing informed consent to baseline.

Exclusion criteria

Exclusion Criteria:

Healthy Subjects

  • Subjects have any medical condition or chronic disease.
  • Subjects have used any of nonprescription drugs within 7 days or prescription drugs within 28 days prior to administration.
  • Subjects experienced a history of keratopathy, fundus disease, increased intraocular pressure, or angle-closure glaucoma. Subjects have any abnormal and clinically significant test for ophthalmic examination during screening.
  • Subjects with a history of orthostatic hypotension or syncope.
  • Subjects with condition that may interfere with the drug absorption, distribution, metabolism and excretion significantly.
  • Subjects had a history of surgery within 3 months prior to administration, or had not recovered, or have a surgical plan during the study.
  • Subjects have any clinically significant abnormal vital signs, laboratory values, and ECGs.
  • Subjects have a history of allergic diseases, or allergic to any substance contained in the formulation
  • Subjects have a positive test for , -Ab, -Ab, or syphilis antibody. Subjects with Stable Schizophrenia
  • According to the , there were other mental disorders except schizophrenia within 6 months before screening period.
  • Assessed by the investigator as having treatment-resistant schizophrenia; past or current diagnosis of neuroleptic malignant syndrome (NMS); anticipated need for antipsychotic regimen modifications during the study period;
  • History of suicide attempts (including actual attempts, interrupted attempts, or failed attempts) or suicidal ideation within the past 6 months, defined as affirmative responses ("yes") to question 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) at screening/baseline;
  • Subjects have used monoamine oxidase inhibitors (MAOI) within 28 days or any dietary supplements/traditional Chinese herbal products within 7 days prior to first dosing.
  • (HbA1c) ≥7% at screening/baseline.
  • Congenital long syndrome; uncontrolled or severe cardiovascular disease, including class II or higher congestive heart failure, unstable angina, myocardial infarction within 6 months prior to screening, or presence of treatment-requiring severe arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes) at screening; resting heart rate \<50 beats per minute (bpm) at screening/baseline; or QTc >450 ms (male) / QTc >460 ms (female) based on Fridericia's formula-corrected measurements at screening/baseline.
  • Subjects experienced a history of keratopathy, fundus disease, increased intraocular pressure, or angle-closure glaucoma. Subjects have any abnormal and clinically significant test for ophthalmic examination during screening.
  • Subjects with a history of orthostatic hypotension or syncope.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    LY03020

    Subjects will take LY03020 from Day 1 to Day 7

    Drug: LY03020

  • Placebo comparator
    Placebo

    Subjects will take Placebo from Day 1 to Day 7

    Drug: Placebo

Interventions

  • administered orally

  • DrugPlacebo

    administered orally

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs).

    Time frame: up to Day 11

Secondary outcomes

  1. Number of participants with clinical laboratory assessment abnormalities.

    Time frame: up to Day 11

  2. Change from Baseline in Positive and Negative Syndrome Scale (PANSS) at Day 11 of subjects with stable schizophrenia

    The total score range is 30 to 210.A higher score is associated with greater illness severity.

    Time frame: up to Day 11

  3. Change from Baseline in Columbia - Suicide Severity Rating Scale (C-SSRS) at Day 11 of subjects with stable schizophrenia

    This scale is divided into three parts, which are evaluated suicidal ideation(5 items \[yes/no\]),intensity of ideation (5 items on 5-point scales; scores range from 0 to 25 with higher scores indicating more intense suicidal ideation),and suicide behavior(actual attempt,interrupted attempt,aborted attempt, preparatory acts or behavior).

    Time frame: up to Day 11

  4. Change from Baseline in Barnes Akathisia Rating Scale (BARS) at Day4 and Day 11 of subjects with stable schizophrenia

    The total score range is 0 to 14.A higher score is associated with greater illness severity.

    Time frame: up to Day 11

  5. Change from Baseline in Simpson-Angus Scale (SAS) at Day4 and Day 11 of subjects with stable schizophrenia

    This scale consists of 10 items, and each question is scored from 0 to 4 points. The Total score range is 0 to 40.A higher score is associated with greater illness severity.

    Time frame: up to Day 11

  6. Maximum observed concentration at steady state (Cmax,ss) of LPM787000048 in plasma

    Time frame: up to Day 11

  7. Minimum observed concentration at steady state (Cmin,ss) of LPM787000048 in plasma

    Time frame: up to Day 11

  8. Area under the concentration- time curve during the dosing interval at steady state (AUC0-τ,ss) of LPM787000048 in plasma

    Time frame: up to Day 11

  9. Area under the concentration-time curve from time zero extrapolated to infinity at steady state (AUC0-∞,ss) of LPM787000048 in plasma

    Time frame: up to Day 11

  10. Time to maximum observed concentration at steady (Tmax,ss) state of LPM787000048 in plasma

    Time frame: up to Day 11

  11. Apparent terminal elimination half-life (t1/2) of LPM787000048 in plasma

    Time frame: up to Day 11

  12. AUC Accumulation Ratio (Ra(AUC)) of LPM787000048 in plasma

    Time frame: up to Day 11

  13. Cmax Accumulation Ratio (Ra(Cmax)) of LPM787000048 in plasma

    Time frame: up to Day 11

  14. Number of participants with vital sign abnormalities.

    Time frame: up to Day 11

  15. Number of participants with 12-lead electrocardiogram abnormalities (ECGs).

    Time frame: up to Day 11

  16. Number of participants with ophthalmic examination abnormalities.

    Time frame: up to Day 11

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07230652
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Aug 20, 2025
Primary completion
Dec 31, 2025 (estimated)
Completion
Feb 28, 2026 (estimated)
Last update
Nov 19, 2025

Study contacts

Yufeng Wang
Contact
wangyufeng@luye.com
86+18665029373

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY03020

Start the discussion